New hope for tough liver cancers? early trial tests Two-Drug punch
NCT ID NCT05644379
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a combination of two drugs—cadonilimab and regorafenib—in 30 adults with advanced liver cancer that has worsened after at least one prior therapy. The goal is to see if the combo can shrink tumors or slow the disease, while also checking for side effects. Because it's a Phase 1 study, the main focus is safety and finding the right dose, not yet proving the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cadonilimab injection and regorafenib tablets
- What this could lead to
- If this works, it could offer a new treatment option for people with advanced liver cancer who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 30 people, so results may not apply to everyone. The drug combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA THAT HAS FAILED AT LEAST ONE PRIOR SYSTEMIC THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300308, China